Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum

被引：12
|
作者：
Shareef, M. S. [1 ]
Munro, L. R. [2 ]
Owen, R. G. [3 ]
Highet, A. S. [1 ]
机构：
[1] York Teaching Hosp, Dept Dermatol, York, N Yorkshire, England
[2] York Teaching Hosp, Dept Haematol, York, N Yorkshire, England
[3] St James Univ Hosp, HMDS Lab, Leeds, W Yorkshire, England
来源：
CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2012年 / 37卷 / 02期
关键词：
MULTIPLE-MYELOMA; MONOCLONAL GAMMOPATHY; CRITERIA;
D O I：
10.1111/j.1365-2230.2011.04219.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.
引用
收藏
页码：146 / 148
页数：3
相关论文
共 50 条
  • [41] Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    Kyle, R. A.
    Durie, B. G. M.
    Rajkumar, S. V.
    Landgren, O.
    Blade, J.
    Merlini, G.
    Kroeger, N.
    Einsele, H.
    Vesole, D. H.
    Dimopoulos, M.
    San Miguel, J.
    Avet-Loiseau, H.
    Hajek, R.
    Chen, W. M.
    Anderson, K. C.
    Ludwig, H.
    Sonneveld, P.
    Pavlovsky, S.
    Palumbo, A.
    Richardson, P. G.
    Barlogie, B.
    Greipp, P.
    Vescio, R.
    Turesson, I.
    Westin, J.
    Boccadoro, M.
    LEUKEMIA, 2010, 24 (06) : 1121 - 1127
  • [42] Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?
    Papachristou, Stella
    Popovic, Djordje S.
    Papanas, Nikolaos
    ADVANCES IN THERAPY, 2022, 39 (06) : 2283 - 2286
  • [43] Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?
    Stella Papachristou
    Djordje S. Popovic
    Nikolaos Papanas
    Advances in Therapy, 2022, 39 : 2283 - 2286
  • [44] Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
    Fernandez de Larrea, C.
    Jimenez, R.
    Rosinol, L.
    Gine, E.
    Tovar, N.
    Cibeira, M. T.
    Fernandez-Aviles, F.
    Martinez, C.
    Rovira, M.
    Blade, J.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 223 - 227
  • [45] Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma
    Zhao, Ranran
    Xie, Yiyu
    Yang, Bingyu
    Wang, Chang
    Huang, Qianlei
    Han, Yue
    Yang, Lulu
    Yan, Shuang
    Wang, Xiaogang
    Fu, Chengcheng
    Wu, Depei
    Wu, Xiaojin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (11): : 3935 - +
  • [46] Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
    C Fernández de Larrea
    R Jiménez
    L Rosiñol
    E Giné
    N Tovar
    M T Cibeira
    F Fernández-Avilés
    C Martínez
    M Rovira
    J Bladé
    Bone Marrow Transplantation, 2014, 49 : 223 - 227
  • [47] Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma
    Suehara, Yasuhito
    Takamatsu, Hiroyuki
    Fukumoto, Kota
    Fujisawa, Manabu
    Narita, Kentaro
    Usui, Yoshiaki
    Takeuchi, Masami
    Endean, Kelly
    Matsue, Kosei
    CANCER SCIENCE, 2017, 108 (02): : 187 - 192
  • [48] Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
    Claveau, Jean-Sebastien
    Savary Belanger, Sophie
    Ahmad, Imran
    Delisle, Jean-Sebastien
    De Guire, Vincent
    Roy, Jean
    LeBlanc, Richard
    BLOOD CANCER JOURNAL, 2022, 12 (01)
  • [49] Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA
    Deshpande, Shayu
    Tytarenko, Ruslana G.
    Wang, Yan
    Boyle, Eileen M.
    Ashby, Cody
    Schinke, Carolina D.
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    Zhan, Fenghuang
    Davies, Faith E.
    Morgan, Gareth J.
    van Rhee, Frits
    Walker, Brian A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (02) : 230 - 240
  • [50] The Development of IgE Multiple Myeloma Following Treatment for Locally Advanced Prostate Cancer
    Fujita, Motoki
    Suzuki, Issei
    Mizuno, Tomoya
    Kobayashi, Hiroyuki
    Kambara, Tsunehito
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
12345